Trevi Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Accounts Payable of -$1.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$276.00K, a 117.76% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.48M.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $123.00K, a 93.16% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$282.00K, a 316.92% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$598.00K, a 137.26% decline from fiscal 2024.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.60M.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$1.05M, a 11755.56% decline from fiscal 2022.
- Trevi Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $9.00K, a 98.92% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.76M 10-Q · filed 2026-08-06 | -$1.64M derived: sum of 3 quarters · filed 2026-08-06 | -$1.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$1.48M 10-Q · filed 2026-05-05 | -$1.36M derived: sum of 2 quarters · filed 2026-05-05 | -$1.64M derived: sum of 3 quarters · filed 2026-05-05 | -$88.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$159.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.40M derived: sum of 3 quarters · filed 2026-08-06 | -$598.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.27M derived: sum of 2 quarters · filed 2026-08-06 | -$721.00K 10-Q · filed 2025-11-13 | $1.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$439.00K 10-Q · filed 2026-08-06 | $1.36M derived: sum of 3 quarters · filed 2026-08-06 | $1.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.99M 10-Q · filed 2026-05-05 | -$194.00K derived: sum of 2 quarters · filed 2026-05-05 | -$64.00K derived: sum of 3 quarters · filed 2026-05-05 | -$682.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.93M derived: sum of 2 quarters · filed 2026-03-17 | $1.31M derived: sum of 3 quarters · filed 2026-03-17 | $1.60M 10-K · filed 2026-03-17 |
| 2024-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$488.00K derived: sum of 2 quarters · filed 2025-11-13 | -$194.00K 10-Q · filed 2025-11-13 | $433.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$618.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$324.00K 10-Q · filed 2025-08-07 | $303.00K derived: sum of 3 quarters · filed 2025-08-07 | $133.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $294.00K 10-Q · filed 2025-05-08 | $921.00K derived: sum of 2 quarters · filed 2025-05-08 | $751.00K derived: sum of 3 quarters · filed 2025-05-08 | $159.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $627.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $457.00K derived: sum of 2 quarters · filed 2025-03-18 | -$135.00K derived: sum of 3 quarters · filed 2025-03-18 | -$1.05M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$762.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.68M 10-Q · filed 2024-11-06 | -$1.14M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.51M 10-Q · filed 2024-08-08 | -$970.00K derived: sum of 3 quarters · filed 2024-08-08 | -$2.44M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$914.00K 10-Q · filed 2024-05-07 | -$378.00K derived: sum of 2 quarters · filed 2024-05-07 | -$1.85M derived: sum of 3 quarters · filed 2024-05-07 | $205.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$932.00K derived: sum of 2 quarters · filed 2024-03-20 | $1.12M derived: sum of 3 quarters · filed 2024-03-20 | $9.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $583.00K derived: sum of 2 quarters · filed 2023-11-09 | -$527.00K 10-Q · filed 2023-11-09 | $88.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $941.00K 10-Q · filed 2023-08-10 | $1.56M derived: sum of 3 quarters · filed 2023-08-10 | $301.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.11M 10-Q · filed 2023-05-11 | -$495.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.75M derived: sum of 3 quarters · filed 2023-05-11 | $936.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$640.00K derived: sum of 2 quarters · filed 2023-03-16 | $2.05M derived: sum of 3 quarters · filed 2023-03-16 | $831.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.43M derived: sum of 2 quarters · filed 2022-11-10 | $216.00K 10-Q · filed 2022-11-10 | $974.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.47M 10-Q · filed 2022-08-11 | $2.23M derived: sum of 3 quarters · filed 2022-08-11 | $327.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$1.22M 10-Q · filed 2022-05-12 | -$457.00K derived: sum of 2 quarters · filed 2022-05-12 | -$2.36M derived: sum of 3 quarters · filed 2022-05-12 | -$1.39M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $758.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$1.14M derived: sum of 2 quarters · filed 2022-03-17 | -$177.00K derived: sum of 3 quarters · filed 2022-03-17 | $417.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | -$1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$935.00K derived: sum of 2 quarters · filed 2021-11-10 | -$341.00K 10-Q · filed 2021-11-10 | $768.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $967.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.56M 10-Q · filed 2021-08-12 | $2.67M derived: sum of 3 quarters · filed 2021-08-12 | $624.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $594.00K 10-Q · filed 2021-05-13 | $1.70M derived: sum of 2 quarters · filed 2021-05-13 | -$343.00K derived: sum of 3 quarters · filed 2021-05-13 | $1.56M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$937.00K derived: sum of 2 quarters · filed 2021-03-25 | $962.00K derived: sum of 3 quarters · filed 2021-03-25 | $777.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$147.00K derived: sum of 2 quarters · filed 2020-11-12 | -$332.00K 10-Q · filed 2020-11-12 | -$390.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $1.71M 10-Q · filed 2020-08-13 | $1.66M derived: sum of 3 quarters · filed 2020-08-13 | $1.60M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$185.00K 10-Q · filed 2020-05-07 | -$243.00K derived: sum of 2 quarters · filed 2020-05-07 | -$299.00K derived: sum of 3 quarters · filed 2020-05-07 | -$228.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$114.00K derived: sum of 2 quarters · filed 2020-03-16 | -$43.00K derived: sum of 3 quarters · filed 2020-03-16 | $66.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $15.00K derived: sum of 2 quarters · filed 2019-11-14 | $124.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $180.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $109.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |